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Abstract 
Background: Emotional lability (EL) is an associated feature of attention-
deficit/hyperactivity disorder (ADHD) in adults, contributing to functional impairment. Yet 
the effect of pharmacological treatments for ADHD on EL symptoms is unknown. We 
conducted a systematic review and meta-analysis to examine the effects of stimulants and 
atomoxetine on symptoms of EL and compare these with the effects on core ADHD 
symptoms. 
Methods: A systematic search was conducted on the databases Embase, PsychInfo, and Ovid 
Medline ® and the clinicaltrials.gov website. We included randomised, double-blind, 
placebo-controlled trials of stimulants and atomoxetine in adults aged 18-60 years, with any 
mental health diagnosis characterised by emotional or mood instability, with at least one 
outcome measure of EL. All identified trials were on adults with ADHD. A random-effects 
meta-analysis with standardised mean difference and 95% confidence intervals was used to 
investigate the effect size on EL and compare this to the effect on core ADHD symptoms. 
 
Results: Of the 3,864 publications identified, nine trials met the inclusion criteria for the 
meta-analysis. Stimulants and atomoxetine led to large mean weighted effect-sizes for on 
ADHD symptoms (n=9, SMD= -0.8, 95% CI:-1.07 to -0.53). EL outcomes showed more 
moderate but definite effects (n=9, SMD= -0.41, 95% CI:-0.57 to -0.25). 
Conclusions: In this meta-analysis, stimulants and atomoxetine were moderately effective 
for EL symptoms, while effect size on core ADHD symptoms was twice as large. 
Methodological issues may partially explain the difference in effect size. Reduced average 
effect size could also reflect heterogeneity of EL with ADHD pharmacotherapy responsive 
and non-responsive sub-types. Our findings indicate that EL may be less responsive than 
ADHD symptoms overall, perhaps indicating the need for adjunctive psychotherapy in some 
cases. To clarify these questions, our findings need replication in studies selecting subjects 
for high EL and targeting EL as the primary outcome. 
Funding: None 
Keywords: Attention-deficit/hyperactivity disorder; Emotional lability; Stimulants; 
Atomoxetine; Systematic review; Meta-analysis  
1. INTRODUCTION 
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition 
affecting around 5% of children.(1) Longitudinal follow-up studies show that ADHD 
frequently persists into adulthood, either as the full blown disorder, or as persistent 
subthreshold levels of symptoms causing impairment,(2,3) with epidemiological surveys 
suggesting an estimated prevalence in adults of around 3-4%.(4) Although inattention, 
hyperactivity and impulsivity are considered to be the core symptoms of ADHD,(5) emotional 
lability (EL), characterised by low frustration tolerance, irritability and mood lability, is a 
commonly associated feature that causes considerable distress to individuals and their 
families.(6) Clinically significant levels of EL are present in around 70-90% of adults with 
ADHD, and is an independent predictor of functional impairments beyond those accounted 
for by inattention and hyperactivity-impulsivity.(7-10) 
 
The importance of EL in adult ADHD was established by Wood, Wender and colleagues, 
who were among the first to describe the syndrome and included affective lability, hot 
temper, and stress intolerance as core symptoms of the disorder.(11,12) The current diagnostic 
and statistical manual of mental disorders (DSM-5) describes such emotional symptoms as 
associated features of ADHD that support the diagnosis.(13) Furthermore, high levels of EL 
are also observed in ADHD patients who do not present with co-occurring mental health 
disorders,(7) indicating that the association of EL with ADHD cannot always be accounted for 
by the presence of comorbid disorders such as bipolar or borderline personality disorders.(14)    
 
Debate as to whether EL reflects a core domain of ADHD in adults is ongoing.(5,15,16) In 
particular it is unclear whether medications such as stimulants and atomoxetine, used in the 
treatment of ADHD, also lead to reductions in EL. Randomized placebo controlled trials in 
adults with ADHD conclusively show that both groups of medications lead to clinically 
significant reductions in symptoms of ADHD symptoms.(9,17-20) However, the effects of drugs 
used to treat ADHD on EL are yet to be established. 
In order to assess the effects of stimulants and atomoxetine on EL in adults we conducted a 
systematic review and meta-analysis of randomised placebo-controlled trials. Our primary 
aim was to quantify the effects of stimulants and atomoxetine on EL. Our secondary aim was 
to contrast the effects of stimulants and atomoxetine on EL with the effects on the core 
ADHD symptoms of inattention and hyperactivity-impulsivity in the same studies. 
2. METHODS 
We conducted a systematic review and meta-analysis in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.(21) 
2.1 Search strategy and selection criteria 
Studies were included if: (a) they were randomised double-blind placebo-controlled trials of 
stimulants or atomoxetine; (b) participants were adults aged 18-60 years with any mental 
health diagnosis associated with EL1; (c) the study measured at least one outcome of 
behavioural change related to EL; (d) for each outcome measure, mean (M) and standard 
deviation (SD) from baseline and follow-up for the placebo and active group were reported or 
                                                          
1 ADHD was not specified as a search term, with the intention of including trials of stimulants and atomoxetine 
on EL in non-ADHD populations. However, all resulting trials were conducted on adults with ADHD. 
obtained upon contacting the authors. Trials published in languages other than English were 
excluded for feasibility reasons of translation. 
A literature search was conducted using pre-specified search terms (see table 1 in appendix 1) 
using the following databases: Embase (1974 to 2015 June 10th), PsychInfo (1806 to June 
week 2, 2015) and Ovid Medline® (1946 to June week 1, 2015). Unpublished or ongoing 
trials were searched on the clinicaltrials.gov website. Authors were contacted to request 
missing data.  
In spite of the official systematic search being stopped in June 2015, there were no new 
clinical trials published meeting the selection criteria of this systematic review up until 2nd 
May, 2017. 
 
To assess for the risk of bias, study quality was assessed by two independent authors (TRM 
& PM) according to PRISMA guidelines and the Cochrane Handbook of Systematic 
Reviews(22) (see table 2 and 3 in appendix 1). TRM and PM then met to discuss assessments 
and reach a consensus on study inclusion. Unresolved classification of studies was arbitrated 
by PA and REC. Studies were classified overall as unclear, low or high risk.  High risk 
studies were excluded. 
Data extraction was performed by TRM and checked by two research assistants. The main 
outcome measures were raw scores of mean and standard deviation of the pre-and post-
treatment measures of EL and DSM-IV ADHD symptoms for active and placebo arms. Intent 
to treat analysis (ITT) was reported.  For trials with a cross-over design, only the initial pre-
cross-over data was included, if available, and treated as a parallel group trial. We used this 
rather conservative approach because there was lack of sufficient data to permit analysis of 
within-individual change (i.e. correlations of scores between conditions were not given). 
Missing data that remained unavailable after contacting authors were not imputed. 
2.2 Outcome measures 
Two outcome domains were included in the meta-analysis: EL and DSM-IV ADHD 
symptoms. EL was measured using the emotion dysregulation subscale of the Wender 
Reimherr Adult Attention Deficit Disorder Scale (WRAADDS-EDS)(11), which combined 
subscales of hot temper, affective lability and emotional over-reactivity, or the emotion 
control subscale of the Behaviour Rating Inventory of Executive Function (BRIEF-A).(23) 
ADHD DSM-IV domains were measured by the investigator-rated, self-rated or informant-
rated Conners Adult ADHD Rating Scale (CAARS)(24), ADHD- Rating Scale (ADHD-RS) or 
the investigator rated WRAADDS.(11) Table 4 (in appendix 1) contains a detailed list of 
measures used in these two domains.  
2.3 Data analysis 
2.3.1 Statistical analyses: Analyses were performed in STATA 11.2.(25) An initial analysis in 
the full sample across the two domains of EL and ADHD symptoms was run, following this, 
subgroup analyses (see below) were conducted. 
We report the SMD calculated as the mean pre-to-post-treatment change, minus the mean 
pre-to-post-placebo group change, divided by the pooled pre-test standard deviation (SD), 
with a bias adjustment. The equation for this method is presented below.(26) Effects sizes were 
classified according to Cohen’s d as follow: d= 0.2, d= 0.5 and d= 0.8 as small, medium and 
large respectively.(27) 
dppc2=C𝑝[
(𝑀𝑝𝑜𝑠𝑡,𝑇−𝑀𝑝𝑟𝑒,𝑇)−(𝑀𝑝𝑜𝑠𝑡,𝐶−𝑀𝑝𝑟𝑒,𝐶)
𝑆𝐷𝑝𝑟𝑒
] 
 
SDpre = √ 
 (𝑛𝑇−1)𝑆𝐷
2
𝑝𝑟𝑒,𝑇+(𝑛𝐶−1)𝑆𝐷
2
𝑝𝑟𝑒,𝐶
𝑛𝑇+𝑛𝐶−2
 
Cp = 1- 
3
4(𝑛𝑇+𝑛𝐶−2)−1
 
 
Note. dppc2=Standardised Mean Difference (SMD), Cp=bias adjustment, M=Mean, T=treatment, C = Control, 
Post = Post-treatment, Pre = Pre-treatment, SD = Standard deviation, n = number of participants. 
 
Given the between-study heterogeneity in terms of study design, trial duration, outcome 
measures and participant characteristics we chose apriori to use random-effects models.(28) A 
nominal level of significance was set at p < .05. The I2 statistic assessed heterogeneity 
between studies. Publication bias was investigated on the basis of funnel plots using Begg & 
Mazumdar’s rank correlation approach and the Egger regression asymmetry test. 
2.3.2 Subgroup analyses: Additional analyses were conducted in subsets of the total sample 
to investigate the stability of the results to the scale used to measure EL (WRAADS-EDS 
versus BRIEF-A) and the class of study medication (stimulants versus atomoxetine). 
2.3.2.1 Outcome measure: EL was measured by either BRIEF-A the emotion control 
subscale(23) or the WRAADDS-EDS.(11) Analyses were performed separately on 
the trials using the BRIEF-A (n=3) and WRAADDS-EDS (n=6). 
 
2.3.2.2 Medication class: Included trials medicated participants with either stimulants or 
atomoxetine. Analyses were conducted separately on studies which used 
stimulants (n=6) and atomoxetine (n=3). 
 
2.3.2.3 Medication class and outcome measure: To check whether the medication gave 
different effect size estimates when controlling for the EL scale (BRIEF-A or 
WRAADDS-EDS) used: we compared the effects of stimulants set against 
atomoxetine, first when EL was measured by the WRAADDS-EDS and then 
when it was measured by the BRIEF-A. 
3. RESULTS 
3.1 Selection of studies 
The initial database search identified 3864 unique publications. 403 abstracts were screened 
against the inclusion criteria, of which 385 were excluded because: the data were already 
used or reported in another publication (n=18); the outcomes were unsuitable (n=44); the 
studies were not randomised controlled trials (n=61), failed to report a placebo group (n=4); 
were open label trials (n=5); used unsuitable medication (medications other than stimulants 
or atomoxetine) (n=14) or population (n=6); were not published in English (n=5); requests for 
data from unpublished trials were not returned successfully (n=24); or the trial was conducted 
on children (n=204). Eighteen full-text articles were subsequently quality appraised and eight 
were excluded because of: an open label design (n=1), unsuitable population (n=2), 
unsuitable design (n=2) and unsuitable outcome (n=3). Ten studies met the inclusion criteria, 
but one of these had to be excluded on the grounds of missing statistics, leaving nine studies 
for inclusion in the final pool for the meta-analysis (see fig. 1 and tables 5, 6 and 7 in 
appendix 1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Prisma flow diagram. 
3.2 Quality and characteristics of studies included in qualitative synthesis 
Nine studies were judged to be of sufficient quality and suitability to be included in the 
quantitative synthesis (see supplementary tables 2 and 3). Randomisation and allocation 
concealment were explicitly described in only one study.(29) In the remainders, this was 
absent or unclear. Means of blinding the participants, personnel and outcome assessment 
were unclear in seven studies, and were only clearly stated in three studies. In one study, 
25.5% of the initially recruited participants dropped out prior to randomisation and another 
12% following randomisation,(19) and in another study, four subjects were eliminated after 
randomisation,(30) raising concerns about the likelihood of selection bias. Study 
characteristics are outlined in supplementary table 5. 
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3.3 Quantitative meta-analysis 
Main effects from the meta-analysis of the nine included studies are summarised in fig. 2. A 
detailed description of these results is available in appendix 2. 
In adults with ADHD treatment with stimulants (OROS-methylphenidate, IR-
methylphenidate, Lis-dexamphetamine, methylphenidate-ER, methylphenidate transdermal 
system) and atomoxetine had a moderate effect on EL (9 studies, SMD = -0.41; 95% CI: -
0.57 to -0.25, z= 5.14, p= 2.7x10-7) and a large effect on ADHD symptoms (9 studies, SMD= 
-0.8; 95% CI: -1.07 to -0.53, z= 5.85, p= 4.9x10-9). There was evidence of high heterogeneity 
in both analyses (X 2= 27.40, I2= 70.8%, p= 0.001; X 2= 72.09, I2 = 88.9%, p < 0.001, 
respectively). There was no evidence of publication bias. 
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Fig 2. Forests plots for meta-analyses across the two main outcome domains ES= Effect size 
3.4 Subgroup analysis 
Main effects from the sub-group analyses are shown in table 8. 
3.4.1 Outcome measure: In the subgroup analysis of studies using the WRAADDS-EDS 
as a measure of EL, a higher treatment effect was found for EL symptoms (6 
studies, SMD= -0.54; 95% CI: -0.75 to -0.33, z= 5.02, p= 5.2x10-7), compared to 
the treatment effect of ADHD medication on EL measured  by the BRIEF-A (3 
studies, SMD= -0.19; 95% CI: -0.33 to -0.05, z= 2.66, p= 0.008). 
 
3.4.2 Medication class: In the subgroup analysis of stimulants only, a higher effect size 
was found on EL symptoms (6 studies, SMD= -0.57; 95% CI: -0.80 to -0.34, z= 
4.90, p= 9.6x10-7), compared to the small effect of atomoxetine on EL (3 studies, 
SMD= -0.21; 95% CI: -0.34 to -0.08, z= 3.25, p= 0.001).  
We also looked at the effects of stimulants and atomoxetine on core ADHD 
symptoms. There was a large treatment effect of stimulants on core ADHD 
symptoms (6 studies, SMD= -0.98; 95 % CI: -1.51 to -0.44, z= 3.58, p= 3.4x10-4) 
and a moderate to large treatment effect of atomoxetine (3 studies, SMD= -0.57; 
95% CI: -0.68 to -0.45, z= 9.76, p= 1.7x10-22). 
 
3.4.3 Medication class and outcome measure: There was a large treatment effect of 
stimulants on EL symptoms when the latter was measured by the WRAADDS-EDS 
(5 studies, SMD= -0.64; 95% CI: -0.91 to -0.36, z= 4.46, p= 8.2x10-6). 
Atomoxetine had a small effect on EL when this was measured by the BRIEF-A (2 
studies, SMD= -0.15; 95% CI: -0.3 to 0, z= 1.97, p= 0.049). 
Table 8 
Subgroup meta-analyses of studies based on: (1) Outcome measure (2) medication class and 
(3) medication class and outcome measure 
 Sub-analyses domain Studies p SMD2 95% CI 
1 WRAADDS-EDS 2,3,6-9 5.2x10-7 -0.54 -0.75 to -0.33 
BRIEF-A-BRI 1,4,5 0.008 -0.19 -0.33 to -0.05 
2 Stimulants on EL 1,2,6-9 9.6x10-7 -0.57 -0.80 to -0.34 
Atomoxetine on EL 3-5 0.001 -0.21 -0.34 to -0.08 
Stimulants on ADHD 1,2,6-9 3.4x10-4 -0.98 -1.51 to -0.44 
Atomoxetine on ADHD 3-5 1.7x10-22 -0.57 -0.68 to -0.45 
3 WRAADDS-EDS +Stimulants 2,6-9 8.2x10-6 -0.64 -0.91 to -0.36 
BRIEF-A-BRI+Atomoxetine 4,5 0.049 -0.15 -0.3 to 0 
Studies 
1= Adler et al. (2013),(31) 2 = Reimherr et al. (2007),(30) 3 = Reimherr et al. (2005),(17) 4 = Adler et al. 
(2014),(29) 5 = Goto et al. (2011),(32) 6 = Wender et al. (2011),(33) 7 = Marchant et al. (2011),(19) 8 = 
Retz et al. (2012),(18) 9 = Rösler et al. (2010)(9) 
  
 
                                                          
2 Negative SMD favours a treatment effect for the active medication (stimulants or atomoxetine); Positive SMD 
favours a treatment effect for the placebo group 
4. DISCUSSION 
We conducted a systematic review and meta-analysis examining the efficacy of stimulants 
(methylphenidate and dexamphetamine/lisdexamfetamine) and atomoxetine on EL in adults. 
In addition, we reported on the effects on ADHD symptoms in the same studies to enable a 
comparison of medication effects on ADHD and EL. Overall we found an effect of stimulants 
and atomoxetine of d=0.41 (CI: -0.57 to -0.25) for EL symptoms and d=0.8 (CI: -1.07 to -
0.53) for ADHD symptoms. Our findings suggest that medications used to treat ADHD also 
have a significant effect on EL, although the effect appears to be more modest on EL 
compared to the effect on the core ADHD symptoms of inattention and hyperactivity-
impulsivity. 
Subgroup analyses indicated that use of the WRAADDS-EDS as an outcome measure might 
lead to greater estimates of clinical effectiveness of ADHD medications on EL than use of the 
BRIEF-A-BRI scale. Subgroup analyses also indicated that stimulants might have a stronger 
effect on reducing EL symptoms than atomoxetine. The greater effects of stimulants 
compared to atomoxetine on EL is in line with independent findings from meta-analyses of 
these medication on core ADHD symptoms.(34,35) 
Consistent with this, the greatest effect on EL was found when analysing the subgroup of 5 
studies which examined the effects of stimulants on EL measured by the WRAADDS-EDS 
(d=0.64). These findings suggests that the effect sizes on EL found in this meta-analysis may 
have been affected by measurement bias or differences in the effects of medication class (i.e. 
stimulants compared to atomoxetine). 
 
In this meta-analysis stimulants and atomoxetine had a two-fold higher treatment effect on 
core ADHD than on EL symptoms. Nevertheless, the moderate treatment effect shows 
clinically significant improvement in the symptoms of EL. One study that was included in the 
qualitative but not the quantitative analysis also found a significant treatment effect of 
atomoxetine compared with placebo on EL. Patients receiving atomoxetine had a significant 
reduction of EL symptoms measured by the BRIEF-A self-rated and informant-rated 
scales.(36) 
 
There were a number of limitations associated with this systematic review. First, despite 
adopting a broad approach towards the selection of studies, many did not meet the eligibility 
criteria and we were only able to include half of those assessed for eligibility (9 studies) in 
the meta-analysis. Secondly, there was substantial heterogeneity with regard to patient 
groups, assessment measures (including differecnes in informant versus self-report vs 
investigator-rated measures) and quality of studies and we therefore had to use random-
effects models that produced wide confidence intervals. Thirdly, all the studies included in 
the meta-analysis relied on  participants who were selected on the grounds of  having high 
levels of core ADHD symptoms, not EL symptoms and this may have contributed to  the 
differential effect sizes. No studies of stimulants or atomoxetine on EL symptoms were found 
for conditions other than ADHD, and none of the trials examined the effects of ADHD 
medication on EL as a primary outcome. Finally, none of the studies reported standard 
deviation  of the change (the difference before and after the intervention) in their effect size 
calculations(26) and so we had to rely on the pre-treatment standard deviation in our 
calculations. This may also have contributed to an underestimation of the true effect size 
associated with EL.(37)  
Another limitation was in relation to the different duration of the included trials that may 
have influenced the result on EL. Therefore a meta-regression of trial duration on both 
ADHD and EL symptoms has been conducted.  However, due to the small number of studies 
and heterogeneity of study characteristic, the results were inadequate. 
 
In conclusion, our findings indicate that EL in patients with ADHD can be treated with 
stimulants or atomoxetine. Although these medications reduce EL, the effects appear to be 
modest by comparison with the effects on the core ADHD symptoms of inattention and 
hyperactivity-impulsivity. Our findings require replication, particularly in patients selected 
for high baseline levels of EL and addressing methodological issues such as measurement 
bias and the potential differential effects of stimulants and atomoxetine. 
 
With regard to the clinical implications of our findings, there are two main possibilities to 
consider. First, that EL reflects a heterogeneous domain of psychopathology that results from 
a number of distinct processes requiring different treatments, much in the same way there are 
different causes for fever or headache. In this scenario it would be important to distinguish 
between stimulant and atomoxetine responsive and non-responsive forms of EL particularly 
in ADHD. An alternative explanation is that stimulants and atomoxetine may have a more 
modest effect on EL overall, perhaps indicating the need for additional targeted psychological 
treatments in some cases. For example, dialectical behaviour therapy has proven efficacy in 
the treatment of emotional instability in people with borderline personality disorder,(38) and 
may also have similar effects in ADHD accompanying pharmacological treatments.(39) 
Further investigations are required using individual patient level data to address these 
questions.  
 
Finally, we did not find any studies of ADHD drug treatments in adult ADHD patients with 
comorbid conditions in which emotional symptoms are also prominent. Further studies are 
therefore required to clarify the role that stimulants or atomoxetine play in the treatment of 
EL in patients with ADHD and co-occurring conditions such as borderline personality 
disorder, or bipolar disorder. Notwithstanding, clinicians should be aware that symptoms of 
EL are often reduced when treating patients with stimluants or atomoxetine who meet 
diagnostic criteria for ADHD. 
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Appendix 1 
Table 1 
Search strategy 
 
 
Database Search Strategy  
Ovid Medline 
(1946 to June week 1, 2015) 
Embase 
(1974 to June 10, 2015) 
PsychInfo 
(1806 to June week 2 , 2015) 
Key Word search: ("affect*" or "oppositional" or "conduct" or "aggression" or 
"mood" or "emotion*" or "instability" or "lability" or "*regulation" or "bipolar") 
and ("stimulants" or "*methylphenidate*" or "*amphetamine*" or 
"*amfetamine*" or "atomoxetine") and ("RCT" or "randomized controlled trial" 
or "randomised controlled trial" or "double blind study" or "clinical trial" or 
"placebo controlled") 
 
Clinicaltrials.gov ("affect*" OR "oppositional" OR "conduct" OR "aggression" OR "mood" OR 
"emotion*" OR "instability" OR "lability" OR "*regulation" OR "bipolar") AND 
("stimulants" OR "*methylphenidate*" OR "*amphetamine*" OR 
"*amfetamine*" OR "atomoxetine") 
Table 2 
Study quality appraisal (scored as low, high or unclear risk) 
 
First Author Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data  
Selective 
reporting 
Other bias Overall 
risk 
Other limitations 
Reimherr et al. (2007) Unclear Unclear Unclear Unclear Unclear Low N/A Unclear No 
Wender et al. (2011) Low Unclear Low Low Low Low N/A Unclear No 
 
Reimherr et al. (2005) 
 
Unclear Unclear Unclear Low Low Low N/A Unclear No 
Adler et al. (2013) 
 
Unclear Low Low Unclear Low Low N/A Unclear No 
Adler et al. (2014) Low Low Low Unclear Low Low Low Unclear No 
Rosler et al. (2010) Unclear Unclear Unclear Unclear Low Low N/A Unclear No 
Marchant et al. (2011)  Low Unclear Unclear Unclear Unclear Low N/A Unclear No 
Goto et al. (2011) Unclear Unclear Unclear Unclear Low Low N/A Unclear No 
Retz et al. (2012)  Low Unclear Unclear Unclear Low Low N/A Unclear No 
Table 3 
Study quality appraisal 
 
First Author Reason if not low risk? Other limitations 
 
Reimherr et al. (2007) Random sequence generation: Insufficient information 
Allocation concealment: Insufficient information 
Blinding of participants and personnel: Procedure unspecified 
Blinding of outcome: Procedure unspecified 
Incomplete outcome data: 6 drop-outs, reasons not stated 
 
N/A 
Wender et al. (2011) Allocation concealment: Insufficient information 
 
N/A 
Reimherr et al. (2005) Random sequence generation: Insufficient information 
Allocation concealment: Unspecified 
Blinding participants and personnel: Insufficient information 
 
N/A 
Adler et al. (2013) Random sequence generation: Unspecified 
Blinding of outcome assessment: Unspecified 
 
N/A  
Adler et al. (2014) Blinding of outcome assessment: Insufficient information 
 
N/A 
Rosler et al. (2010) Random sequence generation: Randomised 
Allocation concealment: Insufficient information 
Blinding of participants: Double-blind 
Blinding of outcome assessment: Insufficient information.  
 
N/A 
Merchant et al. (2011) Allocation concealment: Unspecified 
Blinding of participants and personnel: Unspecified 
Binding of outcome assessment: Unspecified  
Incomplete outcome data: High drop-out rate with no explanations 
N/A 
Goto et al. (2011) Random sequence generation: Unspecified 
Allocation concealment: Unspecified  
Blinding of participants and personnel: Insufficient information.  
Blinding of outcome assessment: Unspecified 
 
N/A 
Retz et al. (2012) Allocation concealment: Insufficient information  
Blinding of participants and personnel: Unspecified 
Binding of outcome assessment: Unspecified 
 
N/A 
 
Table 4 
Detailed breakdown of behavioural rating scales included in the meta-analysis per study by the two outcome measures  
 
First author Domain(s) investigated Rating scale Measure included in meta-analysisa Numbers in Analysis in FU 
   Active  Placebo 
Reimherr et al. (2007) Emotional lability WRAADDS-EDS Emotional lability 20 20 
 ADHD symptoms ADHD-RS  ADHD DSM-IV domains 20 20 
Wender et al. (2011) Emotional lability WRAADDS-EDS Emotional lability 58 57 
 ADHD symptoms WRAADDS ADHD DSM-IV domains 58 57 
Reimherr et al. (2005) Emotional lability WRAADDS-EDS Emotional lability 225 226 
 ADHD symptoms CAARS- Investigator rated ADHD DSM-IV domains 225 226 
Adler et al. (2013) Emotional control BRIEF-A (BRI-emotional 
control subscale)- self-report 
Emotional lability 79 75 
 ADHD symptoms 
 
CAARS- Informant  rated ADHD DSM-IV domains 
 
79 
 
80 
Adler et al. (2014) Emotional control 
 
BRIEF-A (BRI-emotional 
control subscale) 
Emotional lability 161 167 
 ADHD symptoms 
 
CAARS- Investigator rated ADHD DSM-IV domains 192 199 
Rösler et al. (2010) Emotional lability WRAADDS-EDS 
 
Emotional lability  
 
241 118 
 ADHD symptoms CAARS- Self report ADHD DSM-IV domains 239 118 
Marchant et al. (2011) 
 
Emotional lability WRAADDS-EDS Emotional lability 26 33 
 ADHD symptoms CAARS- Investigator rated ADHD DSM-IV domains 26 33 
Goto et al. (2011) Emotional control BRIEF-A (BRI-emotional 
control subscale)- self-report 
Emotional lability 178 190 
 ADHD symptoms CAARS- Investigator rated ADHD DSM-IV domains 191 195 
Retz et al. (2012) Emotional lability WRAADDS-EDS Emotional lability 
 
84 78 
 ADHD symptoms 
 
CAARS- Self report ADHD DSM-IV domains 83 76 
Note. BRIEF-A (BRI)= Behaviour Rating Inventory of Executive Function, behavioural regulation scales (Roth et al., 1996); WRAADDS= Wender-Reimherr Adult 
Attention Deficit Disorder Scale (Wender, 1995); CAARS= Conners’ Adult ADHD Rating Scale (Conners, 1998); ADHD-RS= ADHD- Rating Scale 
Table 5 
Description of studies included in quantitative and qualitative synthesis 
First Author 
Disorder 
Country 
Mean age, years 
(% male) 
Meds  
Supplements (dose/day) Study duration Design 
% completed 
Domain(s) investigated  Numbers recruited 
 Active 1 
 Placebo    Active  Placebo 
Reimherr et al. 
(2007) 
Clinical ADHD 
US 
30.6 
Mixed 
(66) 
OROS- MPH 
(18/27-90mg)  
 Unspecified 4 weeks RCT 
87.24% 
Emotional lability 
 ADHD Symptoms 
20 
20 
20 
20 
Wender et al. (2011) 
ADHD  
USA 
36.9 
(72.41) 
Unmedicated 
Immediate release 
MPH 
45 +/- 14mg day 
 Unspecified 
49 +/- 13 mg/day 
2 weeks RCT 
90.5% 
Emotional lability 
ADHD symptoms 
58 
58 
57 
57 
Reimherr et al. 
(2005) 
Clinical ADHD 
USA/Canada 
41.2 
(65) 
Unmedicated 
ATX (60mg, 90mg, 
120mg) 
 Unspecified 10 weeks RCT 
84.2% 
Emotional lability 
ADHD symptoms  
225 
225 
226 
226 
Adler et al. (2013) 
ADHD symptoms 
USA 
34.2 (active) 34.9 
(placebo) 
(50.6) 
Unmedicated 
Lisdexamphetamine  
30mg, 50mg, 70mg 
(titration) 
 Unspecified 10 weeks RCT 
78.5 %(active) 
66.2% (placebo) 
Emotional lability  
ADHD symptoms 
79 
79 
75 
80 
Adler et al. (2014) 
Clinical ADHD USA 
24.7 
(57.30) 
Unmedicated 
 ATX 
40mg/dayfor min 7 
days (20mg BID), 
80mg/day for min 7 
days (40mg BID). 
Up to 100mg/ day 
(50mg BID) titration 
 Unspecified 12 weeks RCT 
79.73% 
Emotional lability 
ADHD symptoms 
 
161 
192 
167 
199 
Rosler et al. (2010) 
ADHD symptoms 
Germany 
35.2 (active) 
33.8 (placebo) 
(50) 
Unmedicated 
MPH-ER 
10-60mg/day 
 10mg capsules 24 weeks RCT 
30.64% (24% active 
group, 43% placebo 
group) 
Emotional lability 
ADHD symptoms  
 
241 
239 
118 
118 
Merchant et al. 
(2011)   
Clinical ADHD 
USA 
18-65 years 
(unspecified but 
mixed) 
Unmedicated 
MTS  
22% 10-15mg, 28% 
20-25mg, 50% 
30mg 
 
 
Unspecified 4 Weeks RCT 
86.5% 
 
Emotional lability 
ADHD symptoms  
26 
26 
33 
33 
Goto et al. (2011) 
ADHD 
Asia 
32.3  
(47.70) 
unmedicated 
 ATX 
40-120mg/ once 
daily 
 Unspecified 10 weeks RCT 
79.49% ATX 
87.25% Placebo  
Emotional lability 
ADHD symptoms  
 
178 
191 
190 
195 
Retz et al. (2012) 
Clinical ADHD 
Germany 
36.6 (MPH), 38.2 
(PL) 
(38- MPH), (56- PL) 
Unmedicated 
 
MPH-ER  
40,60,80,120 
md/day 
 Unspecified 8 weeks RCT 
95.68% 
Emotional lability 
ADHD symptoms  
 
84 
83 
78 
76 
Table 6 
Characteristics of studies included in qualitative synthesis 
Characteristic Frequencies 
N  (studies) 9 
N  (participants) 2,122 
% Male1 57 
Completion rate 77.8% 
Medication Unmedicated:8 
Unspecified: 1  
 Weighted mean 
Age (years)2 34.02 
Trial duration (weeks) 8.9 
MPH (daily dose) Ranging from 10mg to 120mg/day 
ATX (daily dose) Ranging from 40mg to 120mg/day 
1. One study did not specify sex ratio’s and was therefore not included in this calculation (Marchant et al., 
2011). 
2. One study did not specify the mean age but only gave an age range of the participants eligible to take part in 
the trial, therefore not included in this calculation (Marchant et al., 2011). 
 
Table 7  
Studies excluded at full text stage with reasons (n=8) 
Reason for exclusion Studies 
Open label Sobanski et al. (2012) 
Unsuitable population Drijgers et al. (2012) 
Young et al. (2013) 
Unsuitable design Kavoussi et al. (1993) 
Du Paul et al. (2012) 
Unsuitable outcome Brown et al. (2011) 
Wender et al. (1985) 
Medori et al. (2008) 
Statistics not available Adler et al. (2014) 
Appendix 2 
Detailed description of meta-analyses results 
 
Emotional lability  
Nine trials in 2,036 adults with ADHD examined emotional lability. There was a moderate effect of stimulants 
and atomoxetine on EL (SMD= -0.41; 95% CI: -0.57 to -0.25, z= 5.14, p= 2.7x10-7) with evidence of significant 
high heterogeneity (X 2= 27.40, I2= 70.8%, p= 0.001).  
 
ADHD symptoms 
Nine trials in 2,097 adults with ADHD examined combined ADHD symptoms. There was a large effect of 
stimulants and Atomoxetine on core ADHD symptoms (SMD= -0.8; 95% CI: -1.07 to -0.53, z= 5.85, p= 4.9x10-
9) with evidence of high significant heterogeneity (X 2= 72.09, I2 = 88.9%, p < 0.001). 
 
Emotional lability (WRAADDS-EDS) 
Six trials in 1,186 adults with ADHD examined EL using the emotion dysregulation subscale (EDS) of the 
WRAADDS.  There was a medium effect of stimulants and ATX on EL (SMD= -0.54; 95% CI: -0.75 to -0.33, 
z= 5.02, p= 5.2x10-7) with evidence of significant heterogeneity (X2= 18.78, I2= 73.4%, p= 0.002). 
 
Emotional lability (BRIEF-A-BRI, emotional control subscale) 
Three trials in 850 adults with ADHD examined EL using the emotional control subscale of the BRIEF-A. 
There was a small significant effect of stimulants and ATX on EL (SMD= -0.19; 95% CI: -0.33 to -0.05, z= 
2.66, p= 0.008) with no evidence of heterogeneity (X2= 2.17, I2= 7.9%, p= 0.337). 
 
Emotional lability (Stimulants) 
Six trials in 889 adults with ADHD examined effects of stimulants on EL. There was a medium to large effects 
of stimulant medication on EL (SMD= -0.57; 95% CI: -0.80 to -0.34, z= 4.90, p= 9.6x10-7), with evidence of 
heterogeneity (X2= 17.76, I2= 71.8%, p= 0.003). 
 
Emotional lability (Atomoxetine)  
Three trials in 1,147 adults with ADHD examined effects of Atomoxetine on EL. There was small significant 
effect of ATX on EL (SMD= -0.21; 95% CI: -0.34 to -0.08, z= 3.25, p= 0.001) with no evidence of 
heterogeneity (X2= 2.42, I2= 17.3%, p= 0.298). 
 
ADHD symptoms (Stimulants) 
Six trials in 889 adults with ADHD examined effects of stimulants on core ADHD symptoms. There was a large 
treatment effect of stimulants on ADHD symptoms (SMD= -0.98; 95% CI: -1.51 to -0.44, z= 3.58, p= 3.4x10-4), 
with evidence of significant heterogeneity (X2= 71.47, I2= 93%, p < 0.001). 
 
ADHD symptoms (Atomoxetine) 
Three trials in 1,228 adults with ADHD examined effects of Atomoxetine on core ADHD symptoms. There was 
a moderate to large treatment effect of ATX on ADHD symptoms (SMD= -0.57; 95% CI: -0.68 to -0.45, z= 
9.76, p= 1.7x10-22) with no evidence of heterogeneity (X2= 0.4, I2= 0%, p= 0.817). 
 
Emotional lability (WRAADDS-EDS+stimulants) 
Five trials in735 adults examined the effects of stimulants on EL when measured by the WRAADDS-EDS. 
There was a large treatment effect of stimulants on EL (SMD= -0.64; 95% CI: -0.91 to -0.36, z= 4.46, p= 
8.2x10-6) with evidence of significant heterogeneity (X2= 17.66, I2 = 77.4%, p= 0.001). 
 
Emotional lability (BRIEF-A+Atomoxetine) 
Two trials in 696 adults examined the effects of atomoxetine on EL when this was measured by the BRIEF-A-
BRI. There was a small treatment effect of ATX on EL (SMD= -0.15; 95% CI: -0.3 to 0, z= 1.97, p= 0.049), 
with no evidence of heterogeneity (X2= 0.56, I2= 0%, p= 0.45).
 
